Samples were first screened through immunochromatographic test devices (ICT) devices for HBV (sensitive to HBV surface antigen [HBsAg]) and HCV (sensitive to anti-HCV
Reagent ,HIV Reagent Ag / AT Combo,HBsAg Calibrator
Table-I: Age distribution of study participants and Anti-HCV
For women who matched to both data sources, WEDSS HCV surveillance data were reviewed for evidence of HCV infection (positive laboratory reports for anti-HCV
antibody or RNA).
2) Strong anti-HCV
drugs that became available in the past few years are curing high proportions of people with HCV infection, including people who also have HIV.
Table: HBsAg and anti-HCV
reactive donors among blood donors during 2009 and 2014.
Most of our patients belong to low socio-economic group and find difficult to afford anti-HCV
treatment and related investigations.
Materials and Methods: Sample from 50 anti-HCV
positive blood donors and clinical laboratory patients were analyzed.
Blood samples were collected and processed to confirm the anti-HCV
status and data was collected on pre-tested questionnaires to identify the risk factors.
that is 3rd generation ELISA used in this study that has been reported (100%) sensitive and (98%) specific in different studies.
The patients were screened for the presence of anti-HCV
antibodies by second generation ELISA.
4) There is sustainably higher prevalence of anti-HCV
antibody among haemodialysis patients than in general population indicating greater risk of getting HCV infection among patients undergoing haemodialysis.